Recruiting
Phase 3

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Sponsor:

Idorsia Pharmaceuticals Ltd.

Code:

NCT05672576

Conditions

Lupus Erythematosus, Systemic

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Cenerimod

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information